Navigation Links
Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
Date:9/8/2009

Practices (GCP) guidelines.

The World Health Organization reports that breast cancer is the most commonly diagnosed cancer in women and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that approximately 192,370 U.S. women will be diagnosed with breast cancer in 2009 and 40,170 women will die of the disease in the U.S. alone.

Bavituximab is a monoclonal antibody that targets the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By masking PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab is being tested in combination with chemotherapy in Phase II trials in advanced lung cancer and advanced breast cancer. Interim results in these trials were encouraging, with objective tumor response rates that compare favorably to chemotherapy alone.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara((R)). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregri
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... and TAICHUNG, Taiwan (PRWEB) December 12, 2014 ... less rosy indicators in overall global economic growth, Eugene ... optics and photonics , said in a featured talk ... on 5 December at the National Chung Hsing University ... which is being integrated into future energy supplies and ...
(Date:12/13/2014)... Charlotte, NC (PRWEB) December 13, 2014 ... nearly 3 million people between now and 2030." If ... will become the seventh most populous state in the ... Commerce is gathering at the Future of North Carolina ... We Ready? Do we have the necessary infrastructure in ...
(Date:12/13/2014)... -- Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company focused on ... G. H. Jordan , Ph.D., and David R. ... the total number of directors to eight, seven of ... , Chairman, President, and Chief Executive Officer of Vermillion, ... of Veronica and David to our board of directors.  ...
(Date:12/13/2014)... , Dec. 12, 2014  Vaccinex ... the discovery and development of therapeutic monoclonal ... today announced publication of a manuscript entitled ... inhibits remyelination in neurodegenerative disease" in the ... of Disease*.  The publication highlights an important ...
Breaking Biology Technology:Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 3Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease 2
... RedPrairie Corporation has completed its previously announced acquisition of ... expects to grow to 738 employees at 21 sites ... employees are from MARC. , ,Former MARC CEO Oliver ... organization, under RedPrairie company leader John Jazwiec. , ,"The ...
... an Oracle-based e-mail installation and trying to recover $2.1 ... pilot program that lasted for at least six months ... difficulties cropped up. , ,State CIO Matt Miszewski and ... letter to state agency heads on Friday that the ...
... Amazon.com said on Monday it is acquiring Shopbop, a Madison-based ... up in 1999 as a store on Gorham street called ... as a standalone operation after the acquisition, but Amazon.com will ... not disclosed. With the acquisition, Amazon boosts its selection of ...
Cached Biology Technology:Oracle out, Microsoft in for state e-mail project 2
(Date:11/21/2014)... Strict laws against distracted driving and the ... American and European automotive sector towards gesture recognition technologies. ... that are intuitive and able to retrieve information with ... New analysis from Frost & Sullivan,s Strategic ... Europe and North America ...
(Date:11/18/2014)... , Nov. 18, 2014  The Secure Identity ... Association today jointly announce the formation of The ... of its Identity and Biometric Entry and ... Framework received official support from BORDERPOL, the international ... improve and provide expertise regarding border security, traveler ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock Inc. ... solutions, and MorphoTrust USA (Safran), a ... today announced a strategic partnership to offer comprehensive ... vehicle administration (MVA), airport screening and financial services ... solutions, MorphoTrust serves consumers through a nationwide network ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... SALT LAKE CITY , July 26 Wall Street ... a world leader in content identification solutions, to provide public relations ... in broadcast, government, and professional video trade press worldwide. , ... iPharro Media, based ...
... atmospheric composition, and hence climate. Projections of future climate ... more CO 2 is released from soils in ... due to photosynthesis. Climate changes will also lead to ... methane from wetlands, nitrous oxides from soils, volatile organic ...
... COLUMBUS, Ohio -- Researchers have long known that humans lack ... animal kingdom and even plants -- that reverses severe sun ... this enzyme works at the atomic level to repair sun-damaged ... and skin cancer prevention. In the early online edition ...
Cached Biology News:Wall Street Communications Retained by iPharro Media 2Unaccounted feedbacks from climate-induced ecosystem changes may increase future climate warming 2Researchers discover how key enzyme repairs sun-damaged DNA 2